Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML

Within the International Registry of Childhood Chronic Myeloid Leukemia (CML), we identified 18 patients less than 18 years old at diagnosis of CML who were in the chronic phase and exhibiting a sustained deep molecular response (DMR) to imatinib defined as BCR-ABL1/ABL1 < 0.01% (MR<sup>4&l...

Full description

Bibliographic Details
Main Authors: Frédéric Millot, Meinolf Suttorp, Stéphanie Ragot, Guy Leverger, Jean-Hugues Dalle, Caroline Thomas, Nathalie Cheikh, Brigitte Nelken, Marilyne Poirée, Geneviève Plat, Birgitta Versluys, Birgitte Lausen, Marina Borisevich
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
chronic myeloid leukemia
imatinib
children
Online Access:https://www.mdpi.com/2072-6694/13/16/4102

Internet

https://www.mdpi.com/2072-6694/13/16/4102

Similar Items